JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

CareDx Inc

Отворен

СекторЗдравеопазване

14.88 1.64

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.5

Максимум

15.15

Ключови измерители

By Trading Economics

Приходи

1.8M

-8.6M

Продажби

2M

87M

P/E

Средно за сектора

13.819

37.003

Марж на печалбата

-9.885

Служители

644

EBITDA

9.3M

-4M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+22.7% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

71M

772M

Предишно отваряне

13.24

Предишно затваряне

14.88

Настроения в новините

By Acuity

80%

20%

347 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

CareDx Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2025 г., 23:50 ч. UTC

Горещи акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28.10.2025 г., 23:25 ч. UTC

Печалби

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28.10.2025 г., 23:18 ч. UTC

Печалби

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28.10.2025 г., 22:20 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28.10.2025 г., 22:13 ч. UTC

Печалби

Wal-Mart de Mexico Net Profit Falls in 3Q

28.10.2025 г., 21:38 ч. UTC

Печалби

Correction to Visa Sales Jump Article

28.10.2025 г., 21:17 ч. UTC

Печалби

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28.10.2025 г., 21:07 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- Update

28.10.2025 г., 21:02 ч. UTC

Печалби

Mondelez Tempers Outlook as Costs Rise

28.10.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28.10.2025 г., 23:02 ч. UTC

Печалби

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28.10.2025 г., 23:01 ч. UTC

Печалби

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28.10.2025 г., 22:46 ч. UTC

Печалби

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28.10.2025 г., 22:45 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.6T >000660.SE

28.10.2025 г., 22:44 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.44T >000660.SE

28.10.2025 г., 22:43 ч. UTC

Печалби

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28.10.2025 г., 22:42 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28.10.2025 г., 22:20 ч. UTC

Печалби

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28.10.2025 г., 22:02 ч. UTC

Печалби

Review & Preview: Earnings Extravaganza -- Barrons.com

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28.10.2025 г., 21:20 ч. UTC

Печалби

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28.10.2025 г., 21:19 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28.10.2025 г., 21:18 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение с други в отрасъла

Ценова промяна

CareDx Inc Прогноза

Ценова цел

By TipRanks

22.7% нагоре

12-месечна прогноза

Среден 18 USD  22.7%

Висок 22 USD

Нисък 14 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за CareDx Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

2

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

14.77 / 18.49Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

347 / 373 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat